Eur J Pediatr
Tamoxifen may preserve cardiac function in DMD patients
July 25, 2024
Administering tamoxifen for 48 weeks was generally well-tolerated and helped maintain heart structure and function in boys with Duchenne muscular dystrophy (DMD). Further studies are warranted.
- In this post-hoc analysis of the TAMDMD trial that included boys with DMD (median age, 11 years) who had received either tamoxifen or placebo, researchers identified available echocardiographic data of ambulant patients recruited at one study center and compared before and after treatment.
- Baseline demographic characteristics were similar in participants assigned to placebo (n = 7) or tamoxifen (n = 7).
- Median left ventricular end-diastolic diameter in the placebo group was 39 mm at baseline and 43 mm at study end, compared with 44 mm at baseline and 41 mm after treatment in the tamoxifen group.
- Left ventricular fractional shortening in the placebo group was 35% before and 33% after treatment, while in the tamoxifen group it was 34% at baseline and 35% at study end. No safety signals were detected.
Source:
Henzi BC, et al. (2024, July 3). Eur J Pediatr. Tamoxifen may contribute to preserve cardiac function in Duchenne muscular dystrophy. https://pubmed.ncbi.nlm.nih.gov/38960907/
TRENDING THIS WEEK